THE EFFECT OF SUSTAINED‐RELEASE THEOPHYLLINE IN NOCTURNAL ASTHMA

W. Freeman,G. Packe,R. Cayton
DOI: https://doi.org/10.1111/j.1742-1241.1991.tb08816.x
1991-03-01
Abstract:SUMMARY Nocturnal symptoms are common and often disabling in asthmatic subjects. Furthermore, they often persist, in spite of appropriate dosages of inhaled β2‐agonists and topical steroids. In such a clinical situation, theophylline preparations may have a therapeutic role. This double‐blind, placebo‐controlled, cross‐over trial was designed to evaluate the effectiveness of a twice‐daily Bioavail slow‐release theophylline capsule in a group of out‐patient asthmatics, with a history of nocturnal and/or early morning wheeze or chest tightness. Theophylline was initially prescribed and monitored in an ‘open’ phase to obtain the drug dosage required to achieve a serum level in the therapeutic range of 10‐20 mg/l. In the ten patients who completed the study, serum theophylline levels were stable throughout.
What problem does this paper attempt to address?